North Dakota State Investment Board Makes New Investment in IQVIA Holdings Inc. $IQV

North Dakota State Investment Board purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,792 shares of the medical research company’s stock, valued at approximately $1,306,000.

Several other institutional investors have also recently made changes to their positions in IQV. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA during the fourth quarter worth about $25,000. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after buying an additional 134 shares during the last quarter. International Assets Investment Management LLC bought a new position in IQVIA during the fourth quarter valued at approximately $27,000. Westside Investment Management Inc. lifted its stake in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new stake in shares of IQVIA in the 3rd quarter valued at approximately $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on IQV. JPMorgan Chase & Co. lowered their price objective on IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $174.00 to $213.00 in a research note on Monday, March 9th. Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Finally, UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $225.69.

IQVIA Trading Up 0.2%

IQV opened at $173.10 on Wednesday. The stock’s fifty day moving average is $170.00 and its two-hundred day moving average is $198.42. The company has a market capitalization of $28.89 billion, a P/E ratio of 21.45, a PEG ratio of 1.65 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.